2025 Updates in Clinical Oncology: Program 1 - Lung and Brain скачать в хорошем качестве

2025 Updates in Clinical Oncology: Program 1 - Lung and Brain

Enduring Activity: 2025 Updates in Clinical Oncology: Program 1 -- Lung and Brain Evaluation and Credit: https://www.surveymonkey.com/r/2025UC... Target Audience This program is for physicians, physician assistants, nurse practitioners, pharmacists, nurses and other health care providers in the practice specialties of family medicine, obstetrics/gynecology, internal medicine, neurology, oncology, pathology, preventive medicine, radiology, and surgery. Statement of Need This lecture has been designed to meet the needs of educational needs of clinicians by presenting advancements and guidelines for improved patient care in all primary areas of clinical oncology. Objectives 1) Discuss new strategies for the prevention and diagnosis of cancer. 2) Identify state-of-the-art treatment protocols for oncology patients. 3) Describe standard therapeutic practices and the application of the newest therapies in the treatment of cancer patients. Presentations: 1. "Optimizing Lung Cancer Outcomes: Evolving Roles in Neoadjuvant and Adjuvant Therapy" Adam D. Lye, M.D. Physician, Norton Healthcare Louisville, KY 2. "Transformative Therapies in Stage IV Lung Cancer" Travis P. Spaulding, M.D. Oncologist, Norton Cancer Institute Norton Healthcare Louisville, KY 3. "Gamma Tile Treatment for Brain Tumors" Parag R. Sevak, M.D. Radiation Oncologist, Norton Cancer Institute Norton Healthcare Louisville, KY Planning Committee The planners for this activity include the course director, John T. Hamm, M.D., FACP, FASCO; and the planning committee members, Karen Busse, M.S., CCMEC; Pamela Jacobs, MHA, BSN, R.N., CRNI, OCN; Sandra Stroud, B.A., CCMEC; Sally Sturgeon, DNP, R.N., SANE-A, AFN-BC; and Lauren White, CAP-OM. Disclosure With the exception of Dr. Parag Sevak, the remaining speakers and planners of this activity do not have a relevant financial relationship with an ineligible company. Dr. Sevak has disclosed a relevant financial relationship with Gamma Tiles (research). This relevant financial relationship with an ineligible company has been successfully mitigated prior to this activity. Physician Credits Accreditation This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education. Designation Norton Healthcare designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information related to CME, contact the Norton Healthcare Center for Continuing Medical, Provider & Nursing Education at (502) 446-5955 or cme@nortonhealthcare.org. Nursing Credits Norton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 1.0 contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance. For more information related to nursing credits, contact Sally Sturgeon, DNP, R.N., SANE-A, AFN-BC, at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Date of Original Release | February 1, 2026 Course Termination Date | February 1, 2028 Contact Information | Center for Continuing Medical Education cme@nortonhealthcare.org References 1. Janne, P, et. al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine 2025; DOI; 10.1056/NEJMoa2510308. 2. https://www.nejm.org/doi/full/10.1056... 3. Chen, Zhiwei et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomized, double-blind, phase 3 trial. The Lancet, Volume 0, Issue 0. 4. https://www.thelancet.com/journals/la.... 5. Choudhury Noura J et al. Lurbinectedln in extensive-stage small-cell lung cancer. The Lancet, volume 405, Issue 10495, 2104-2106. 6. https://www.thelancet.com/journals/la.... 7. Keynote-671 OS -- Lancet 2024. 8. CheckMate 77T -- ASCO 2025 9. Aegen update -- WCLC 2024 10. CheckMate 816 OS -- NEJM 2025 11. Impower010 -- JCO 2025 12. NeoAdaura -- ASCO 2025 13. NCCN v. 2025 NSCLC Guidelines